FULL DISCLOSURE: This is sponsored content for DiagnaMed Holdings.
DiagnaMed Holdings (CSE: DMED) is moving forward with the commercialization of CERVAI, its brain health AI platform. The company this morning disclosed that it has launched a provider network to enhance the distribution of the platform.
The CERVAI Healthcare Provider Network, which is now open for enrollment, has been designed as a partnership program that aims to expand access to the CERVAI platform for healthcare providers. The platform currently consists of a Brain Age estimation and Brain Health Assessment tool, the latter of which includes a novel EEG headset and machine learning to generate clinician-observed measures and a brain health score.
Sponsored · Cambria Gold Mines
READ: DiagnaMed Expects Brain Health AI Platform To Be Commercialized In Q4 2023
Future version of the platform intend to incorporate OpenAI’s GPT platform to develop personalized treatment plans based on the results generated from the Brain Health Assessment tool.
“As we near the commercial launch for CERVAI™, our novel brain health AI platform, we are excited to build our network of healthcare providers seeking to provide value added services, research and clinical care for their patients who want to take control of their brain health. Similarly, we will soon launch additional network programs for enterprise organizations, athletic teams, and personal at-home use,” commented Fabio Chianelli, CEO of DiagnaMed.
DiagnaMed Holdings last traded at $0.04 on the CSE.
FULL DISCLOSURE: DiagnaMed Holdings is a client of Canacom Group, the parent company of The Deep Dive. Canacom Group is currently long the equity of DiagnaMed Holdings. The author has been compensated to cover DiagnaMed Holdings on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.
